Human ST3GAL1 PharmaGenie ELISA Kit (SBRS1119)

The ST3GAL1 sialyltransferase immunoassay from Assay Genie supports quantitative measurement of human ST3 beta-galactoside alpha-2,3-sialyltransferase 1 in human cell culture supernatant, plasma, and serum matrices. ST3GAL1 catalyzes the transfer of sialic acid from CMP-N-acetylneuraminic acid to terminal galactose residues on glycoproteins and glycolipids, contributing to the biosynthesis of sialyl Lewis a and sialyl Lewis x carbohydrate epitopes linked to altered cell surface glycosylation during oncogenesis.

Investigators in glycobiology, tumor biology, and translational oncology apply this enzyme-linked immunosorbent kit to characterize changes in ST3GAL1 expression across disease models including pancreatic ductal adenocarcinoma, colorectal carcinoma, and breast carcinoma systems, where aberrant O-glycan sialylation has been associated with metastatic spread and immune evasion. The kit is supplied as a pack of reagents sized for 96 determinations, with pre-coated microplate wells, biotinylated detection antibody, recombinant protein standards, streptavidin-enzyme conjugate, and assay diluent buffer.

Marketed for research use only, the reagents support laboratory investigation of glycosyltransferase activity, biomarker discovery, and pathway studies in vitro. Each plate includes calibrator curve points to interpolate sample concentrations across the assay dynamic range.